Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

March 21, 2019
Samir Undevia, MD

Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.

Sponsor: SWOG (formerly the Southwest Oncology Group)

  • Resectable stage III or IV melanoma
  • No brain metastases
  • No treatment prior to surgery
  • No previous immunotherapy or vaccine therapy
  • No current or history of pneumonitis requiring steroid therapy
  • No active infections requiring systemic therapy
  • At least 18 years old

10-12 years

Accepting Participants
Sofia Mikac, BSN